Founded in mid-2022, T-Oncology is a Swiss biotech startup dedicated to transforming cancer treatment through innovative therapies. Our Mission: Give hope to patients by creating advanced therapeutics that offer safe and more effective treatment options, affordable for patients worldwide.
Products, services, technology
A multi-target pipeline of sdAb light chain (VL) solutions (ADC/ CAR-T & bispecifics) to address unmet oncology treatment needs for safest patient treatment options.
- http://www.toncology.com
- +41 79 691 60 02
- Send an email
- Thomas Christian Weh
Some insights
T-Oncology advances patient care by pioneering small domain antibody research into safe, effective oncology treatments, addressing unmet needs, improving survival rates and the patient quality of life.
T-Oncology fosters a culture of innovation, collaboration, and purpose. All team members are thrilled and dedicated to contribute to life-saving breakthroughs, and still finding time to support each others and being actively engagein the science community.
Any scientist focused on the needs of patients is a role model. At the end it is the strength of the patients, their families and thier care givers fighting cancer who are the true role models of resilience and believe, that it can be done.
The core strength of T-Oncology's team is passion. Blended with years of industry experience, technical knowledge and an understanding of the responsibilities to develop drugs for humans expertise and manage the partners' investments makes us prepared to overcoming challenges and being impactful.
The feedback I receive is that I am doing what I believe in.
Switzerland and the biotech ecosystem are an amazing place to connect with top research institutions, getting access to information and financing. This blend will be ensuring to succeed when it comes to regulatory guidance, leveraging a skilled workforce, and succesfully scale.
Any founder and early team members are excited to have an exchange and learn from the experiences they are willing to share.